C ardiogenic shock, the most common cause of in-hospital mortality following acute myocardial infarction (AMI), complicates between 5% and 10% of cases (1). Although the past few decades have seen a decline in early mortality in patients with cardiogenic shock-largely due to increased rates of early revascularization (2) and improved adjunctive pharmacotherapy-in-hospital mortality remains high, at up to 50% (3). Although cardiogenic shock is more common among patients with ST-segment elevation myocardial infarction (STEMI), patients with non-ST-segment elevation myocardial infarction (NSTEMI) tend to have higher baseline risk profiles. Some registries report no difference in early mortality according to AMI subtype in patients with cardiogenic shock (4). Others report higher mortality for NSTEMI patients, potentially explained by their less favorable risk profiles and higher rates of early revascularization for STEMI (5).
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For patients who survive the index hospitalization, the effect of shock on adverse outcomes diminishes over time, with similar mortality beyond 1 year in shock and nonshock patients (6, 7) . However, very little is known regarding interim, early post-discharge outcomes in this population. reported that they have no relationships relevant to the contents of this paper to disclose. Although cardiogenic shock patients who survived hospitalization were sicker in the acute phase than their nonshock counterparts (with a strong preponderance of STEMI, at 62% vs. 29%, respectively; p < 0.001), they had more favorable cardiovascular risk profiles at baseline. Moreover, twice the proportion of cardiogenic shock patients was discharged to nursing care facilities rather than home, implying that these patients remained more frail on discharge.
It is not surprising, then, that early mortality was higher for these patients; however, having survived the early post-discharge phase, as they returned closer to their lower-risk baseline with time, so too did their risk of adverse events.
The very high mortality rates for myocardial infarction patients with cardiogenic shock demonstrate that conventional management is inadequate.
This should motivate us to search for potentially Finally, the study offers no information on causespecific mortality or detailed treatment of patients in the acute phase, in particular, the use of mechanical circulatory support devices. However, the
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